July 24, 2020
OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients
New pancreatic cancer trial, NeoPancONE, launches across Canada
Adapted from Pancreatic Cancer Canada’s press release.
OICR’s PanCuRx team and collaborators have launched NeoPancONE, a Phase II clinical trial that will evaluate a potentially curative treatment strategy for operable pancreatic cancer. The trial, which is supported by Pancreatic Cancer Canada, will recruit patients at 10 cancer centres across the country to evaluate the effectiveness and feasibility of peri-operative chemotherapy – chemo treatment before and after surgery.
Typically, only 50 per cent of pancreatic cancer patients receive chemotherapy after surgery due to a range of personal and health reasons. NeoPancONE will help evaluate whether chemotherapy treatment before surgery can help extend the lives of these individuals.Continue reading – OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients
June 24, 2020
Philanthropic donation moves The Alex U. Soyka Pancreatic Cancer Research Project: An International Partnership into Phase II
Ontario-Israel collaboration to explore personalized treatment and improved diagnostics for pancreatic cancer
Toronto – (June 24, 2020) A second significant multi-year commitment from Sylvia M. G. Soyka, Director, and the Alex U. Soyka Foundation to the Canadian Friends of the Hebrew University of Jerusalem (CFHU) will allow researchers from the Ontario Institute for Cancer Research (OICR), the Hebrew University’s Institute for Medical Research Israel-Canada (IMRIC) and Sheba Medical Center to conduct The Alex U. Soyka Pancreatic Cancer Research Project: Phase II – An International Partnership (Soyka Project).
Phase II builds upon the outstanding achievements of Phase I of the Soyka Project by fostering further collaboration between Israeli and Ontario researchers, focusing on three main research avenues in pancreatic cancer – to develop effective patient-specific treatment courses, address the challenges of tumour cell heterogeneity and create new methods for early-stage diagnosis.
As a measure of its impact so far, Phase I of the Soyka Project has been cited in more than 18 peer-reviewed papers on pancreatic cancer including manuscripts in the prestigious journals Nature Genetics, Nature Medicine and Cancer Cell. Phase II of the Soyka Project will provide eight of Israel’s leading cancer researchers with funds to explore the molecular origins of pancreatic cancer, as well as novel diagnostic biomarkers and therapeutic approaches. These fellowships are key to the multi-disciplinary approach of the Soyka Project and this round of funding will see new scientists joining the team with expertise in single-cell RNA sequencing and bioinformatics, some of the most advanced approaches used in cancer research today.
A central component of Phase II is to increase the opportunity for patients at the Sheba Medical Center in Israel to be molecularly profiled according to the COMPASS clinical trial guidelines. COMPASS is a world-leading initiative led by Dr. Steven Gallinger, supported by OICR and based at the University Health Network in Toronto, that uses genomic and transcriptomic information from patient tumours to personalize treatment with the aim of improving outcomes. The data collected through COMPASS will also be used by Soyka Project scientists to dig deep into the inner workings of pancreatic cancer.
“I feel proud and privileged to fund Phase II of this international collaboration in pancreatic cancer research,” says Sylvia M. G. Soyka. “In the world of cancer research, much progress has been made in recent years, but pancreatic cancer remains a deadly disease with a dismal less than 10% five-year survival rate. When we started Phase I in 2014, the five-year survival rate was less than 5%, but there is clearly a long way to go. In 2010, my father, a man fully engaged in every aspect of life who took great pains to look after his health, the sort of person who was going to live well forever, was diagnosed out of the blue and died three months to the day later. The Soyka Project is his legacy. Phase I was highly successful, in no small part due to the collaboration of the dedicated scientists, within and between the teams, which created new directions. In the context of today’s world, I feel strongly that the fact of the collaboration alone, which requires both trust and generosity of spirit, sets an important example which should be emulated. The rewards of Phase II will be ours as well as theirs.”
“I am extremely thankful to Sylvia Soyka for her generous funding of this cutting-edge research program. Pancreatic cancer is notoriously difficult to detect and treat and patients need better options,” says Dr. Laszlo Radvanyi, President and Scientific Director, OICR. “The Soyka Project is an incredible example of the benefits of international scientific collaboration that will reveal important insights into detecting pancreatic cancer earlier and developing precision medicine tools for improved treatment. We are thrilled to continue this important work with our partners in Israel.”
“Sylvia Soyka is the driving force and inspiration behind The Alex U. Soyka Pancreatic Cancer Research Project that started six years ago and now, her recent generous donation will allow the second phase of research,” says Prof. Haya Lorberboum-Galski, Chair of IMRIC. “Her longstanding support is of vast importance to the researchers at IMRIC as it will enable us to continue our ongoing endeavour to decipher the basic molecular aspects of one of the deadliest cancers – pancreatic cancer. We hope this exciting work, in collaboration with OICR, will lead to new approaches for early diagnosis, prevention, treatment and a cure.”
“Sylvia Soyka is an exemplary philanthropic leader who decided to tackle one of the most challenging and underfunded cancers,” says Rami Kleinmann, President and CEO of CFHU. “Together with an outstanding team of researchers and practitioners from Canada and Israel, she managed to help make substantial progress in understanding the disease. We hope that with the current funding of Phase II, we will be able to take it even further.”
About The Alex U. Soyka Pancreatic Cancer Research Project: Phase II – An International Partnership (Soyka Project)
Alex U. Soyka was a committed supporter of the Hebrew University through the CFHU in Montreal. Following his death from pancreatic cancer in 2010, his daughter Sylvia M. G. Soyka, Director, and the Alex U. Soyka Foundation, made a multi-year funding commitment to CFHU to launch The Alex U. Soyka Pancreatic Cancer Research Project.
About the Ontario Institute for Cancer Research (OICR)
OICR is a collaborative, not-for-profit research institute funded by the Government of Ontario. We conduct and enable high-impact translational cancer research to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. For more information visit https://oicr.on.ca/
About the Institute for Medical Research Israel-Canada (IMRIC)
The Institute conducts basic and translational/precision research in the field of biomedicine with a main focus on cancer research. The Institute scientists work in a multidisciplinary enterprise that is essential for understanding most of the diseases that currently challenge medical science, including cancer, for the benefit of patients all over the world. For more information visit https://medicine.ekmd.huji.ac.il/En/academicUnits/imric/Pages/Default.aspx
About the Canadian Friends of Hebrew University (CFHU)
CFHU facilitates academic and research partnerships between Canada and Israel, as well as establishes scholarships, supports research and cultivates student and faculty exchanges. Albert Einstein, Martin Buber, Chaim Weizmann and Sigmund Freud were among the university’s founders whose genius inspired a university without limits or borders. CFHU is dedicated to supporting Hebrew University in its efforts to remain one of the most innovative learning institutions in the world.
OICR media contact
Ontario Institute for Cancer Research
CFHU media contact
Senior National Director, Communication
Canadian Friends of the Hebrew University
416-485-8000, Ext. 111
January 13, 2020
Researchers identify five subtypes of pancreatic cancer, uncovering new opportunities for targeted treatment of the aggressive disease
Toronto – (January 13, 2020) Researchers at the Ontario Institute for Cancer Research (OICR) and the University Health Network (UHN) have discovered detailed new information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease.
The study, published today in Nature Genetics, represents the most comprehensive analysis of the molecular subtypes of pancreatic cancer to date. Through detailed genomic and transcriptomic analyses, the research group identified five distinct subtypes of the disease (Basal-like-A, Basal-like-B, Classical-A, Classical-B, and Hybrid) with unique molecular properties that could be targeted with novel chemotherapies, biologics and immunotherapies.
“Therapy development for pancreatic cancer has been hindered by an incomplete knowledge of the molecular subtypes of this deadly disease,” says lead author Dr. Faiyaz Notta, Co-Leader of OICR’s Pancreatic Cancer Translational Research Initiative (PanCuRx) and Scientist at UHN’s Princess Margaret Cancer Centre. “By rigorously analyzing advanced pancreatic cancers – which is the stage of disease that most patients have when they’re diagnosed – we were able to create a framework. This will help us develop better predictive models of disease progression that can assist in personalizing treatment decisions and lead to new targeted therapies.”
The study is based on data from more than 300 patients with both early stage and advanced pancreatic cancer who participated in COMPASS, a first-of-its-kind clinical trial that is breaking new ground in discovery science and personalized pancreatic cancer treatment. COMPASS is enabled by advanced pathology laboratory techniques at UHN and OICR, and next generation sequencing at OICR.
“Most pancreatic cancer research is focused solely on early stage – or resectable – tumours, but in reality, pancreatic cancer is often found in patients after it has advanced and spread to other organs,” says Notta. “COMPASS allowed us to look into these advanced cancers while treating these patients, develop a better understanding of the biology behind metastatic pancreatic cancer, and shed light on the mechanisms driving disease progression.”
Interestingly, the Basal-like-A subtype, which had been difficult to observe before this study, was linked with a specific genetic abnormality. Most of the Basal-like-A tumours harboured several copies of a mutated KRAS gene, also known as a genetic amplification of mutant KRAS. The research group hypothesizes that some of the subtypes arise from specific genetic changes that occur as pancreatic cancer develops.
“This research opens new doors for therapeutic development,” says Dr. Steven Gallinger, Co-Leader of OICR’s PanCuRx, Surgical Oncologist at UHN and Senior Investigator, Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital. “We look forward to capitalizing on the promise of these discoveries, building on our understanding of pancreatic cancer subtypes, and bringing new treatments to patients with the disease.”
This research was supported by OICR through funding provided by the Government of Ontario, and by the Wallace McCain Centre for Pancreatic Cancer by the Princess Margaret Cancer Foundation, the Terry Fox Research Institute, the Canadian Cancer Society Research Institute, the Pancreatic Cancer Canada Foundation, the Canadian Friends of the Hebrew University and the Cancer Research Society (no. 23383).
March 6, 2018
VANCOUVER – Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease.
“For many years it’s been hopeless from a patient perspective, and we are hoping to help shift this,” says Dr. Daniel Renouf (BC Cancer, University of British Columbia) who, along with Dr. David Schaeffer (UBC, Vancouver General Hospital), is leading a $5-million pan-Canadian, precision medicine initiative recently funded by the Terry Fox Research Institute.
A lack of early detection tests. Few known symptoms. Very limited treatment options. No known biomarkers that can be used to direct therapy. These are among the clinical challenges team EPPIC, short for Enhanced Pancreatic Cancer Profiling for Individualized Care, is tackling over the next five years to improve personalized treatments for patients with pancreatic ductal adenocarcinoma (PDAC), a disease with just a nine per cent five-year survival rate.
January 30, 2018
Early results from COMPASS trial demonstrate benefits of using genomic sequencing to guide treatment for pancreatic cancer
Genomic profiling has allowed physicians to customize treatments for patients with many types of cancer, but bringing this technology to bear against advanced pancreatic cancer has proven to be extremely difficult. OICR’s pancreatic cancer Translational Research Initiative, called PanCuRx, has been conducting a first-of-its-kind clinical trial called COMPASS to evaluate the feasibility of using real time genomic sequencing in pancreatic cancer care. The research team recently reported early results from the trial, which show how they overcame the challenges of genomic profiling specific to pancreatic cancer and gained new insights about the disease.
PanCuRx is focused on improving treatment for pancreatic adenocarcinoma (PDAC), the most common form of pancreatic cancer and the fourth leading cause of cancer death in Canada. The group’s approach centres around understanding the genetics and biology of PDAC to inform the selection of therapies, as well as the development of new treatments.
May 25, 2017
OICR launches five all-star teams of Ontario scientists to tackle some of the deadliest forms of cancer
Great strides have been made in cancer research, but much work remains to develop better treatments for the most lethal cancers and to advance new anti-cancer technologies. OICR is taking on a new approach, building on the success of the Institute’s first ten years and Ontario’s strength in particular cancer research areas. Reza Moridi, Ontario’s Minister of Research, Innovation and Science announced that the Institute is funding five collaborative, cross-disciplinary and inter-institutional Translational Research Initiatives (TRIs) with a total of $24 million over the next two years.
The TRIs will bring together some of the top cancer researchers in Ontario and be led by internationally renowned Ontario scientists. Each team will focus on a certain type of cancer or therapeutic technology. To maximize the positive impact of research on patients, the TRIs all incorporate clinical trials into their design. The TRIs, which were selected by an International Scientific Review Panel, are:
- Acute Leukemia TRI (led by Drs. John Dick and Aaron Schimmer at the University Health Network (UHN))
- Brain Cancer TRI (led by Drs. Peter Dirks and Michael Taylor at SickKids)
- Immuno-oncology TRI (ACTION) (led by Drs. John Bell and Marcus Butler at The Ottawa Hospital and UHN)
- Ovarian Cancer TRI (led by Drs. Amit Oza and Rob Rottapel at UHN)
- Pancreatic Cancer TRI (PanCuRx) (led by Dr. Steven Gallinger at UHN)
The funding will also support Early Prostate Cancer Developmental Projects led by Drs. Paul Boutros and George Rodriguez.
“In just over 10 years, the Ontario Institute for Cancer Research has become a global centre of excellence that is moving the province to the forefront of discovery and innovation in cancer research. It is home to outstanding Ontario scientists, who are working together to ease the burden of cancer in our province and around the world,” said Moridi.
“Collaboration and translational research are key to seeing that the innovative technologies being developed in Ontario reach the clinic and help patients,” said Mr. Peter Goodhand, President of OICR. “These TRIs represent a unique and significant opportunity to impact clinical cancer care in the province.”
— SickKids_TheHospital (@SickKidsNews) May 25, 2017
— UHN (@UHN_News) May 25, 2017
— The Ottawa Hospital (@OttawaHospital) May 25, 2017
May 25, 2017
OICR launches five large-scale Ontario research initiatives to combat some of the most deadly cancers
Toronto (May 25, 2017) – Reza Moridi, Ontario’s Minister of Research, Innovation and Science, today announced the Ontario Institute for Cancer Research is launching five unique, cross-disciplinary, multi-institutional Translational Research Initiatives (TRIs), each focused on a single type of or treatment approach to cancer. With $24 million in funding over two years, the TRIs will bring together world-leading scientists to tackle some of the most difficult to treat cancers and test innovative solutions to some of the most serious challenges in cancer today.
The TRIs build on Ontario’s proven strengths in areas such as stem cells, immuno-oncology, pediatric cancers, genomics, clinical trials and informatics. Working together, the province’s top scientists and clinicians will accelerate the development of much needed solutions for patients around the globe, with a focus on acute leukemia and brain, ovarian and pancreatic cancers. Each TRI includes clinical trials to maximize patient impact.
February 10, 2017
OICR researchers to be part of Cancer Research UK’s Grand Challenge helping to answer cancer’s biggest questions
Toronto (February 10, 2017) – Ontario Institute for Cancer Research (OICR) researchers Drs. Lincoln Stein and Steven Gallinger have been announced as members of one of the first global research teams to be recipients of Cancer Research UK’s Grand Challenge.
The Grand Challenge aims to help overcome the biggest challenges facing cancer research in a global effort to beat cancer sooner.
Stein and Gallinger’s pioneering team will study samples from five continents to understand the DNA damage associated with different cancers, to understand what causes them and if they can be prevented. The project will be led by Professor Mike Stratton at the Wellcome Trust Sanger Institute, Cambridge, with collaborators from France, the U.S. and U.K.
October 21, 2016
OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies
Pancreas cancer is one of the most aggressive and deadly forms of the disease. According to the Canadian Cancer Society, only 8 percent of pancreas cancer patients survive more than five years after diagnosis. OICR’s PanCuRx Translational Research Initiative has recently published the results of an international collaboration that increases understanding of this complex disease and how to treat it based on a patient’s unique profile.
October 12, 2016
The findings provide important insights into how pancreas cancer develops and spreads and new strategies for better understanding one of the mostly deadly types of cancer.
Toronto (October 12, 2016) – Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreas cancer is so aggressive.
June 1, 2015
The Ontario Institute for Cancer Research invests $4.6 million to support pancreatic cancer research
TORONTO, ON (June 1, 2015) – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer. The multidisciplinary program brings together researchers from the fields of genomics, pathology, cancer biology and informatics, as well as clinician scientists, who will collaboratively work to better understand pancreatic cancer on a molecular level and use this understanding to develop better, more personalized diagnostics and therapies for patients. The research will focus on pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.
“There have been huge scientific advances over the past few decades on many types of cancer, but statistics on pancreatic cancer have remained largely unchanged,” said Dr. Tom Hudson, President and Scientific Director of OICR. “OICR is proud today to announce support for PanCuRx and help to improve these statistics and bring new solutions to patients.”
Initial funding for the initiative was provided last spring by Sylvia M. G. Soyka, director, and the Board of Trustees of the SMGS Family Foundation to the Canadian Friends of the Hebrew University (CFHU). The focus of this funding is to find and identify the molecular drivers behind metastatic pancreatic cancer. Researchers at the Institute for Medical Research Israel-Canada (IMRIC) at the Hebrew University of Jerusalem and Sheba Medical Center in Israel and at OICR in Toronto are currently working collaboratively to achieve this goal.
“This new funding will help tackle one of the least understood types of cancer. Ontario’s innovative and collaborative research community, together with our partners in Israel, are well suited for this challenge to discover new solutions and treatments that will benefit patients worldwide,” said Reza Moridi, Ontario Minister of Research and Innovation.
PanCuRx’s unique, collaborative design will allow teams of researchers to pursue research and clinical questions in parallel, with a tight link between clinical practice and lab research. The research will also be highly integrated with the Princess Margaret Cancer Centre’s translational PDAC program, ensuring that in addition to increasing understanding of the disease more generally, the research will directly inform the treatment strategy of patients who participate.
“The focus of PanCuRx is to ensure we bring the patients closer to the research and the research closer to the patients,” said Dr. Steven Gallinger, Surgical Oncologist and Head, Hepatobiliary/Pancreatic Surgical Oncology Program at University Health Network, Senior Investigator, Samuel Lunenfeld Research Institute of Mount Sinai Hospital and leader of the PanCuRx initiative. “By working together among disciplines and between the research and clinical components we feel much more can be accomplished and we have a real chance of making an impact on improving outcomes for PDAC patients.”
“I am alive today because of the groundbreaking treatment I received from Dr. Gallinger, Dr. Malcolm Moore and their team,” said Libby Znaimer, a prominent Canadian journalist and pancreatic cancer survivor. Znaimer received therapy targeted at the molecular level to the specific subtype of pancreatic cancer she was diagnosed with, an avenue of diagnosis and treatment that this new funding will further explore. “This summer I will celebrate seven years since diagnosis. We need more research to ensure that outcomes like mine become the norm, rather than a rare exception.”
Pancreatic ductal adenocarcinoma (PDAC) makes up approximately 85 per cent of pancreatic cancer cases. In 2014, an estimated 4,700 Canadians were diagnosed with PDAC and 4,400 died from the disease. It is the fourth leading cause of cancer death in Canada and the current five-year survival rate of 7.7 per cent is the lowest of all cancers. While the number of people dying from common cancers such as breast and colon cancer has dropped dramatically over the past 30 years, there have been only slight improvements for PDAC. It is estimated that PDAC will be the second leading cause of cancer death in North America within 10 years.